vimarsana.com

நிறுவனம் க்கு பயன்படுத்தப்பட்டது புற்றுநோய் அறிவியல் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Metabolic inhibitor IACS-6274 shows early antitumor effects in underserved patients

Credit: MD Anderson Cancer Center HOUSTON The glutaminase (GLS1) inhibitor IACS-6274, discovered and developed by The University of Texas MD Anderson Cancer Center s Therapeutics Discovery division, appears to be well-tolerated with successful target inhibition and early signs of anti-tumor activity in a biomarker-driven Phase I trial. Interim results of the study will be presented at the 2021 American Society for Clinical Oncology (ASCO) Annual Meeting on June 4. On the trial, 17 of 20 evaluable patients achieved a best response of stable disease, with a disease control rate of 60% at 12 weeks. Six patients with biomarker-defined advanced cancers had meaningful durable disease stabilization for greater than six months, with evidence of tumor shrinkage.

MD Anderson researchers highlight advances in clinical studies at the AACR Annual Meeting 2021

Credit: MD Anderson Cancer Center HOUSTON Early phase clinical trials conducted by researchers from The University of Texas MD Anderson Cancer Center show promising results for patients with RET fusion-positive cancers, high-grade (HGG) and low-grade glioma (LGG) and ovarian cancer. The results, presented today at the virtual American Association for Cancer Research (AACR) Annual Meeting 2021, showcase the researchers ongoing efforts to advance clinical studies and expand potential indications of approved drugs to develop a platform for more effective treatments and to improve patient outcomes. FDA-approved selpercatinib shows clinical benefits for RET fusion-positive cancers beyond lung and thyroid cancers (Abstract CT011)

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.